🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#ESMOMembers vote for the leaders who will shape ESMO’s future. Vote now for the Directors of Education, Public Policy & Membership - and the Chair and members of the Nomination Committee 📽️ Watch the ESMO President’s message 🔗 Vote now: ow.ly/XX3W50VZQyL FabriceAndre

Amazing lineup for this virtual event. Speakers include PIs of phase 3 IO trials across solid tumors Drs. Solange Peters Tom Powles John Heymach Ronan Kelly Tina Cascone Mark Yarchoan Grainne O'Kane translational scientists & FDA regulatory perspectives Sign up now! #LCSM

📢 The phase 3 DeLLphi-304 trial confirms it: Tarlatamab is clearly superior to chemo in 2nd-line treatment. Tarlatamab secures its place as a new 2L standard. 🧾 Presented by Charles M. Rudin (MD) 🔗 NEJM nejm.org/doi/full/10.10… #ASCO25 #LungCancer #BiTE #Immunotherapy

⏳ Early bird registration for #WCLC25 ends June 6! Don’t miss reduced rates to attend the world’s largest meeting on lung cancer. 📅 Sept. 6–9, 2025 📍 Barcelona, Spain Register now → wclc.iaslc.org/registration/ #IASLC #LungCancer #OncologyConference #GlobalOncology

Update from the Phase 2 PHAROS Study of encorafenib + binimetinib in #BRAF V600E NSCLC JTO & JTO CRR. As 1L therapy, RR 75%, DOR 40m, PFS 30m, 3y OS rate 53%. In previously treated, RR 46%, DOR 16.7m, PFS 9.3m, OS 22.7m, 3y OS 29%. jto.org/article/S1556-…

🔬 I’m proud to share our latest publication in The Journal of Liquid Biopsy — a consensus article from ISLB on the minimal requirements for ctDNA testing in solid tumors. 🧪 It has been an honor to contribute alongside a fantastic group of international experts in Liquid Biopsy

🚨 The ANZHNCS ASM 2025 Final Program is LIVE! 🌍✨ Join top global leaders shaping head & neck cancer care this August in Adelaide. 🔗 Full program: vist.ly/3n6ew8m 🔗 Register: vist.ly/3n6ew8r #ANZHNCSASM2025 #ANZHNCS25 #HealthcareInnovation #RegisterNow

🚨A comprehensive review on immunotherapy rechallange! ✅Even it is not effective in kidney cancer, can still be effective in select tumors, especially after discontinuation-related progression (not resistance-driven). ➡️Non-small cell lung cancer data show outcomes depend on

Announcing the first EVER Journal of Clinical Oncology Art of Oncology Narrative Medicine Contest! 🎉✍️🎗️🩺🎉 We're looking for essays that explore the human experience of cancer and reflect on the experience of trainees and early career hematologists/oncologists. Apply Now! ascopubs.org/jco/art-oncolo…

Excited to meet in one of Asia’s best cities to learn from global colleagues! Submit your abstract now! #ESMOAsia25

Loving this review on small cell lung cancer BiTE Rafeh Naqash, MD & team! Such a 💵 slide to explain CRS/ICANS toxicity ascopubs.org/doi/10.1200/ED…

Great work Ben Tran and team! Been waiting for chemo sparing strategies in this cohort! ANZUP Peter Mac Cancer Centre

China has now surpassed all other countries in number of new oncology clinical trials launched each year, AND also number of novel active substances (NAS) for cancers launched. IQVIA iqvia.com/library/videos…

Exciting drug development scene in Asia-Pacific! Looking forward to engaging with colleagues from across the region in upcoming ESMO - Eur. Oncology Asia Targeted Anticancer Therapies meeting in HK. esmo.org/meeting-calend…

Delighted to present episode 2 of ESMO - Eur. Oncology Women4Oncology’s Diary of an Oncology Leader, with Chair of Thoracic Oncology Marina Garassino from UniversityofChicago Great insights on: - role of community in skill-building - self belief - thinking big ‘Don’t wait. Just start’ OncoAlert #LCSM

Global trends in lung cancer reported Lung Cancer Journal. Notable for general increase in lung cancer incidence and mortality in women, esp France (incidence) and Norway (mortality). Increases noted in some countries despite decrease in tobacco use (Japan). lungcancerjournal.info/article/S0169-…

Clinical benefit and cost of plasma-first next-generation sequencing in patients with newly diagnosed advanced non-small cell lung cancer in Ireland: The PLAN study - European Journal of Cancer ejcancer.com/article/S0959-… Jarushka Naidoo

🚨 Just out in NEJM: #KEYNOTE689 💉🧠 Periop #pembrolizumab (neoadj + adj) + surgery + RT/CRT improves EFS in resectable LA-#HNSCC. First +ve phase 3 in this space! 🔥 🔹 EFS @ 3 yrs CPS ≥10: 59.8% vs 45.9% CPS ≥1: 58.2% vs 44.9% All pts: 57.6% vs 46.4% 📉 HR ~0.66–0.73 🧪 MPR: